Open Payments

U Of U Hospitals & Clinics

Type
Teaching hospital
Where
Salt Lake City, UT
Medicare CCN
460009
Received
$34,982,734 in 2,581 records, 2024 ($3,840,742 general, $31,141,991 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment248$3,840,742
2024Research payment2,333$31,141,991

By company

CompanyRecordsAmountYears
Novavax Inc9$5,045,0012024
Merck Sharp & Dohme LLC42$2,874,1552024
PFIZER INC.207$2,632,2872024
AstraZeneca Pharmaceuticals LP15$2,177,9612024
Amgen Inc.22$2,126,3562024
ABBVIE INC.348$1,866,6732024
Boston Scientific Corporation34$1,842,7542024
Janssen Research & Development, LLC148$1,478,5872024
Blueprint Medicines Corporation66$1,063,7202024
AstraZeneca UK Limited7$881,8842024
Astellas US Technologies4$814,6102024
Genentech, Inc.22$726,5562024
Eli Lilly and Company14$603,4542024
Biogen, Inc.9$546,8772024
Medtronic, Inc.25$470,2142024
Amicus Therapeutics, Inc.10$440,9082024
United Therapeutics Corporation53$389,0332024
Boehringer Ingelheim Pharmaceuticals, Inc.9$379,3112024
Sarepta Therapeutics, Inc.101$352,2312024
VERTEX PHARMACEUTICALS INCORPORATED9$337,0142024
Takeda Pharmaceuticals U.S.A., Inc.118$315,8332024
Sumitomo Pharma America, Inc.28$314,7462024
Alexion Pharmaceuticals, Inc.6$305,8532024
Regeneron Pharmaceuticals, Inc.62$281,7112024
Epizyme, Inc.125$278,1402024
PTC Therapeutics, Inc.16$277,9802024
Medical Device Business Services, Inc.51$276,3892024
GENZYME CORPORATION26$274,5872024
LivaNova USA, Inc.9$272,8932024
Olympus Corporation of the Americas5$269,6352024
SPR Therapeutics, Inc10$268,4662024
JAZZ PHARMACEUTICALS INC.8$222,0392024
Olympus America Inc.26$179,6412024
National Marrow Donor Program17$176,8512024
MED-EL Corporation5$175,7552024
Stryker Corporation36$171,7072024
Daiichi Sankyo Inc.202$167,8062024
Ultragenyx Pharmaceutical Inc.30$164,1082024
CSL Behring30$158,2892024
Intuitive Surgical, Inc.15$148,6002024
BioMarin Pharmaceutical Inc.14$145,2502024
Cortex, Inc.2$136,7682024
BeiGene, Ltd.57$136,1472024
Alcon Research LLC2$128,2972024
ALBIREO PHARMA, INC.3$120,1052024
Immedica Pharma US, Inc.19$114,1442024
Siemens Medical Solutions USA, Inc.11$109,6062024
Abbott Laboratories34$104,3622024
Ipsen Pharma SAS49$103,6632024
Neurocrine BioSciences, Inc.3$103,0002024

By nature of payment

NatureRecordsAmount
Research payment2,333$31,141,991
Grant71$2,723,244
Space rental or facility fees (teaching hospital only)87$402,347
Debt forgiveness26$173,188
Royalty or License8$167,515
Compensation for services other than consulting, including serving as faculty or as a speaker at a v25$135,338
Long term medical supply or device loan12$115,557
Education11$66,306
Consulting Fee5$50,944
Charitable Contribution3$6,300

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Merck Sharp & Dohme LLC$531,714Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2024
2024-12-31Merck Sharp & Dohme LLC$454,672Research paymentCash or cash equivalentWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary 2024
2024-12-31Merck Sharp & Dohme LLC$226,095Research paymentCash or cash equivalentWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31Merck Sharp & Dohme LLC$145,274Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb2024
2024-12-31Merck Sharp & Dohme LLC$143,029Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera2024
2024-12-31Merck Sharp & Dohme LLC$84,151Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2024
2024-12-31Merck Sharp & Dohme LLC$60,232Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYPhase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma2024
2024-12-31Siemens Medical Solutions USA, Inc.$55,818Research paymentIn-kind items and servicesMultitom Rax Device, DI - X-Ray ProductsAssessment of novel 3D imaging features of Multitom Rax2024
2024-12-31Merck Sharp & Dohme LLC$41,732Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i2024
2024-12-31Merck Sharp & Dohme LLC$29,496Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb2024
2024-12-31AstraZeneca Pharmaceuticals LP$26,931Research paymentIn-kind items and servicesA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Posit2024
2024-12-31Merck Sharp & Dohme LLC$18,589Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792024
2024-12-31Merck Sharp & Dohme LLC$16,890Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit2024
2024-12-31Intuitive Surgical, Inc.$16,850Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$14,107Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2024
2024-12-31Merck Sharp & Dohme LLC$14,006Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand2024
2024-12-31Merck Sharp & Dohme LLC$12,934Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera2024
2024-12-31Merck Sharp & Dohme LLC$11,346Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2024
2024-12-31Merck Sharp & Dohme LLC$10,073Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination wit2024
2024-12-31Merck Sharp & Dohme LLC$8,762Research paymentIn-kind items and services Drug, INFECTIOUS DISEASEA Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health2024
2024-12-31Merck Sharp & Dohme LLC$7,764Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEA Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-2024
2024-12-31Merck Sharp & Dohme LLC$6,253Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary 2024
2024-12-31Merck Sharp & Dohme LLC$5,349Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYPhase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma2024
2024-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Merck Sharp & Dohme LLC$4,089Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31Intuitive Surgical, Inc.$3,400Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Sumitomo Pharma America, Inc.$3,018Research paymentCash or cash equivalentA Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-36542024
2024-12-31ABBVIE INC.$1,750Research paymentIn-kind items and servicesA Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o2024
2024-12-31ABBVIE INC.$1,656Research paymentIn-kind items and servicesVYALEV Drug, NEUROSCIENCEM20-098 ABBV-951 aPD2024
2024-12-31Merck Sharp & Dohme LLC$1,617Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2024
2024-12-31ABBVIE INC.$1,320Research paymentIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE3110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265)2024
2024-12-31Regeneron Pharmaceuticals, Inc.$890Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYI-SPY 2 TRIAL (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS 2024
2024-12-31Stryker Corporation$870Debt forgivenessCash or cash equivalent2024
2024-12-31Philips North America LLC$732Long term medical supply or device loanIn-kind items and services(8269) DreamStation Cpap Device, Medical Device2024
2024-12-31ABBVIE INC.$600Research paymentIn-kind items and servicesM23-385 ABBV-706 Ph 1 2L-4L SCLC2024
2024-12-31Acerta Pharma LLC$592Research paymentIn-kind items and servicesCALQUENCE Drug, OncologyA Phase half, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemi2024
2024-12-31Merck Sharp & Dohme LLC$586Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary 2024
2024-12-31ABBVIE INC.$392Research paymentIn-kind items and servicesA Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Tolerability, and Pharmacodynamics of CVL-82024
2024-12-31Sumitomo Pharma America, Inc.$360Research paymentCash or cash equivalentA Phase 1 Study of DSP-0390 in Patients with Recurrent High-grade Glioma2024
2024-12-31Stryker Corporation$176Debt forgivenessCash or cash equivalent2024
2024-12-31Merck Sharp & Dohme LLC$76Research paymentIn-kind items and servicesSIVEXTRO Drug, INFECTIOUS DISEASEA Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpa2024
2024-12-31Stryker Corporation$55Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2024
2024-12-30Janssen Research & Development, LLC$70,758Research paymentCash or cash equivalentERLEADA Drug, OncologyA Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Depriva2024
2024-12-30ABBVIE INC.$21,198Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2024
2024-12-30Intuitive Surgical, Inc.$16,000Consulting FeeCash or cash equivalentDa Vinci Surgical System Device, SURGERY2024
2024-12-30ABBVIE INC.$5,744Research paymentCash or cash equivalentA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi2024
2024-12-30Janssen Research & Development, LLC$4,368Research paymentCash or cash equivalentA Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for2024
2024-12-30Janssen Research & Development, LLC$3,300Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2024
2024-12-30Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-12-30Janssen Research & Development, LLC$557Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-12-30Janssen Research & Development, LLC$355Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2024
2024-12-28Biogen, Inc.$1,000GrantCash or cash equivalent2024
2024-12-27Boston Scientific Corporation$35,000GrantCash or cash equivalent Device, General - Therapies_ENDO2024
2024-12-27AKEBIA THERAPEUTICS INC$2,700Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$2,500Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$2,500Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$2,200Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$2,200Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$1,837Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$1,537Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27Janssen Research & Development, LLC$1,500Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-12-27Medacta USA, Inc.$816Research paymentCash or cash equivalentM-Vizion Femoral Revision System Device, HIPMedacta M-Vizion Macroscopic Radiographic Study, Multi-center, Post-Market Outcomes Study2024
2024-12-27AKEBIA THERAPEUTICS INC$800Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27AKEBIA THERAPEUTICS INC$405Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27Sarepta Therapeutics, Inc.$318Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-27AKEBIA THERAPEUTICS INC$241Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-27Sarepta Therapeutics, Inc.$93Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-27Sarepta Therapeutics, Inc.$25Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-26Biogen, Inc.$336,911Research paymentCash or cash equivalentSPINRAZA Biological, NeurologyAn Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational St2024
2024-12-26Amicus Therapeutics, Inc.$19,063Research paymentCash or cash equivalentPOMBILITI Drug, Pompe DiseaseA Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD2024
2024-12-26Sarepta Therapeutics, Inc.$3,343Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-26Janssen Research & Development, LLC$327Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-12-24ABBVIE INC.$15,021Research paymentCash or cash equivalentUBRELVY Drug, NEUROSCIENCEStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch2024
2024-12-24United Therapeutics Corporation$7,209Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-12-24United Therapeutics Corporation$5,265Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2024
2024-12-24United Therapeutics Corporation$3,082Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24United Therapeutics Corporation$2,363Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-23Merck Sharp & Dohme LLC$228,519Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera2024
2024-12-23Genentech, Inc.$18,619Research paymentCash or cash equivalentCotellic Drug, BioOncologyCobimetinib in patients with RAS activated CMML2024
2024-12-23Janssen Research & Development, LLC$7,143Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-12-23Janssen Research & Development, LLC$3,110Research paymentCash or cash equivalentA Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitre2024
2024-12-22Philips North America LLC$5,459Research paymentIn-kind items and services(3082) NIBP Cuffs Device, Medical DeviceNon-Invasive Blood Pressure Validation Study2024
2024-12-20Genentech, Inc.$150,000Research paymentCash or cash equivalent2024
2024-12-20PFIZER INC.$10,378Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-12-20Blueprint Medicines Corporation$5,406Research paymentCash or cash equivalentA Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients 2024
2024-12-20Blueprint Medicines Corporation$1,925Research paymentCash or cash equivalentA Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients 2024
2024-12-20Daiichi Sankyo Inc.$1,565Research paymentCash or cash equivalentDS1103-0742024
2024-12-19AstraZeneca UK Limited$52,694Research paymentCash or cash equivalentSAPHNELO Biological, Inflammation and AutoimmunityA Phase III,Randomized,Double blind,Parallel group,Placebo controlled Study to Evaluate the Pharmacokinetics,Pharmacodyn2024
2024-12-19ABBVIE INC.$9,549Research paymentCash or cash equivalentUBRELVY Drug, NEUROSCIENCELong-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai2024
2024-12-19Janssen Research & Development, LLC$3,689Research paymentCash or cash equivalentA Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred2024
2024-12-19Janssen Research & Development, LLC$2,510Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-12-19Epizyme, Inc.$2,476Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-12-19Epizyme, Inc.$2,394Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-12-19CSL Behring$2,342Research paymentCash or cash equivalentHEMGENIX Biological, HematologyPhase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral 2024
2024-12-19Neurelis, Inc.$2,000EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2024
2024-12-19Ipsen Pharma SAS$1,835Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-12-19Ipsen Pharma SAS$1,835Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2024
2024-12-19Epizyme, Inc.$1,333Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-12-19Epizyme, Inc.$1,333Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-12-18UCB SA$14,584Research paymentCash or cash equivalentA MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFE2024
2024-12-18BioMarin Pharmaceutical Inc.$13,063Research paymentCash or cash equivalentPALYNZIQ Drug, PKUPhase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participatin2024
2024-12-18AstraZeneca UK Limited$12,284Research paymentCash or cash equivalentFASENRA Biological, RespiratoryA Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extensi2024
2024-12-18Scientia Vascular$8,000Research paymentCash or cash equivalentColossus Device, NeuroResearch Grant - Colossus Posterior and Educational Research Grant2024
2024-12-18Takeda Pharmaceuticals U.S.A., Inc.$750Research paymentCash or cash equivalentA PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL2024
2024-12-18Takeda Pharmaceuticals U.S.A., Inc.$341Research paymentCash or cash equivalentA PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL2024
2024-12-17Boston Scientific Corporation$692,749GrantIn-kind items and services Device, General - Therapies_ENDO2024
2024-12-17Astellas US Technologies$224,720Research paymentIn-kind items and servicesPadcev Drug, OncologyENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with2024
2024-12-17Medtronic, Inc.$103,076Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2024
2024-12-17PFIZER INC.$19,854Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2024
2024-12-17Medical Device Business Services, Inc.$6,262Research paymentCash or cash equivalentHEALIX KNOTLESS PEEK Device, Sports SurgicalMitek Device Registry2024
2024-12-17Medical Device Business Services, Inc.$1,977Research paymentCash or cash equivalentHEALIX KNOTLESS PEEK Device, Sports SurgicalMitek Device Registry2024
2024-12-17Medical Device Business Services, Inc.$900Research paymentCash or cash equivalentHEALIX KNOTLESS PEEK Device, Sports SurgicalMitek Device Registry2024
2024-12-17Medical Device Business Services, Inc.$600Research paymentCash or cash equivalentHEALIX KNOTLESS PEEK Device, Sports SurgicalMitek Device Registry2024
2024-12-17Boston Scientific Corporation$495Research paymentCash or cash equivalentTACTRA Device, TACTRA_UROIT MATTERS2024
2024-12-16PFIZER INC.$44,921Research paymentCash or cash equivalentA PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS2024
2024-12-16Janssen Research & Development, LLC$9,037Research paymentCash or cash equivalentA Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred2024
2024-12-16Janssen Research & Development, LLC$8,866Research paymentCash or cash equivalentCARVYKTI Drug, OncologyA Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B2024
2024-12-16PFIZER INC.$3,513Research paymentCash or cash equivalentPADCEV Biological, OncologyAN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHE2024
2024-12-16Janssen Research & Development, LLC$2,918Research paymentCash or cash equivalentA Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitre2024
2024-12-16Lucid Diagnostics Inc.$750Research paymentCash or cash equivalentBE22024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-13Amicus Therapeutics, Inc.$122,075Research paymentCash or cash equivalentPOMBILITI Drug, Pompe DiseaseA Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD2024
2024-12-13Sarepta Therapeutics, Inc.$11,000Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$10,800Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Merck Sharp & Dohme LLC$10,800Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit2024
2024-12-13Janssen Research & Development, LLC$5,706Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po2024
2024-12-13Sarepta Therapeutics, Inc.$5,486Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$5,400Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Janssen Research & Development, LLC$3,335Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$2,500Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Medical Device Business Services, Inc.$2,300Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-13Sarepta Therapeutics, Inc.$2,184Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Janssen Research & Development, LLC$1,925Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2024
2024-12-13Sarepta Therapeutics, Inc.$1,785Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$1,785Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$1,538Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$1,350Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$1,225Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$800Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Sarepta Therapeutics, Inc.$675Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$445Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$445Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$257Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$257Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Sarepta Therapeutics, Inc.$250Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$250Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Sarepta Therapeutics, Inc.$250Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$200Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13Sarepta Therapeutics, Inc.$200Research paymentCash or cash equivalentSRP-9001-3052024
2024-12-13CSL Behring$71Research paymentIn-kind items and servicesPhase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral 2024
2024-12-12Novavax Inc$268,885Research paymentCash or cash equivalentNOVAVAX COVID-19 VACCINE, ADJUVANTED Biological, vaccineStudy of Health care workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-192024
2024-12-12Alexion Pharmaceuticals, Inc.$100,000Research paymentCash or cash equivalentEpidemiology and Characterization of Serum Biomarkers of Autoimmunity in NMOSD Patients from the United States Departmen2024
2024-12-12ABBVIE INC.$42,908Research paymentCash or cash equivalentSKYRIZI Biological, IMMUNOLOGYA Study to Assess Adverse Events Change in Disease Activity and How the Drug Moves Through the Body in Children With Juv2024
2024-12-12Sebela Women's Health Inc.$4,282Research paymentCash or cash equivalentA PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2024
2024-12-12Regeneron Pharmaceuticals, Inc.$2,725Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN2024
2024-12-12Regeneron Pharmaceuticals, Inc.$1,851Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN2024
2024-12-12Regeneron Pharmaceuticals, Inc.$200Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN2024
2024-12-11Intuitive Surgical, Inc.$16,000Consulting FeeCash or cash equivalentDa Vinci Surgical System Device, SURGERY2024
2024-12-11Ultragenyx Pharmaceutical Inc.$5,163Research paymentCash or cash equivalentDTX401-CL3012024
2024-12-11Novo Nordisk Inc$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-11Takeda Pharmaceuticals U.S.A., Inc.$2,700Research paymentCash or cash equivalentA STUDY OF SOTICLESTAT AS AN ADD-ON THERAPY IN CHILDREN AND ADULTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME2024
2024-12-11Smith+Nephew, Inc.$2,344Space rental or facility fees (teaching hospital only)Cash or cash equivalentENDOBUTTON Device, Sports Med Knee2024
2024-12-11AKEBIA THERAPEUTICS INC$2,200Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-11KLS-Martin L.P.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-11AKEBIA THERAPEUTICS INC$1,875Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-11SPR Therapeutics, Inc$1,542Research paymentCash or cash equivalentSPRINT PNS System Device, Pain ManagementThe MONARCH (Multicenter Occipital Neuralgia and Cervicogenic Headache) Case Series Study: Treatment of Head Pain with t2024
2024-12-11AKEBIA THERAPEUTICS INC$1,225Research paymentCash or cash equivalentAuryxia Drug, NephrologyA 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper2024
2024-12-11Day One Biopharmaceuticals$778Research paymentCash or cash equivalentOJEMDA Drug, ONCOLOGYDAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh2024
2024-12-11Day One Biopharmaceuticals$631Research paymentCash or cash equivalentOJEMDA Drug, ONCOLOGYDAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh2024
2024-12-11Day One Biopharmaceuticals$130Research paymentCash or cash equivalentOJEMDA Drug, ONCOLOGYDAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh2024
2024-12-11Day One Biopharmaceuticals$102Research paymentCash or cash equivalentOJEMDA Drug, ONCOLOGYDAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh2024
2024-12-10Boehringer Ingelheim Pharmaceuticals, Inc.$49,417Research paymentCash or cash equivalentPhII - BI 1839100 in IPF associated with chronic cough2024
2024-12-10ABK Biomedical USA, Inc.$24,770Research paymentCash or cash equivalentEye90 microspheres Device, Radiation Therapy DevicesRadioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma 2024
2024-12-10Ipsen Pharma SAS$203Research paymentCash or cash equivalentDysport Drug, NeurologyA Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Deve2024
2024-12-09Astellas US Technologies$140,450Research paymentIn-kind items and servicesPadcev Drug, OncologyENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with2024
2024-12-09Janssen Research & Development, LLC$81,423Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2024
2024-12-09Janssen Research & Development, LLC$11,415Research paymentCash or cash equivalentA Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance2024
2024-12-09GENZYME CORPORATION$5,690Research paymentCash or cash equivalentA Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and S2024
2024-12-09Olympus America Inc.$1,214Debt forgivenessIn-kind items and services2024
2024-12-09CSL Behring$256Research paymentIn-kind items and servicesAn Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ2024
2024-12-06Takeda Pharmaceuticals U.S.A., Inc.$20,300Research paymentCash or cash equivalentVPRIV Biological, GENETIC DISEASEGAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH G2024
2024-12-06Stryker Corporation$15,233Research paymentCash or cash equivalentINSIGNIA Device, JOINT REPLACEMENT HIPS, KNEESEARLY PERFORMANCE OF THE INSIGNIA STEM IN PRIMARY DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY2024
2024-12-06Agios Pharmaceuticals, Inc.$15,046Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseAG348-C-0112024
2024-12-06PROGENICS PHARMACEUTICALS, INC.$10,465Research paymentCash or cash equivalentPYLARIFY Drug, RADIOPHARMACEUTICALPYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR2024
2024-12-06Blueprint Medicines Corporation$8,423Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis2024
2024-12-06PFIZER INC.$7,890Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYTALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN2024
2024-12-06Janssen Research & Development, LLC$5,660Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2024
2024-12-06Stryker Corporation$1,500Research paymentCash or cash equivalentAEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIESTORNIER PERFORM STEMLESS REVERSE IDE STUDY (19B-W-PERFORM-R)2024
2024-12-06ARGENX US, INC.$1,450Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyAn Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigi2024
2024-12-06Stryker Corporation$1,242Research paymentCash or cash equivalentAEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIESPERFORM HUMERAL SYSTEM STUDY (PHS)2024
2024-12-06Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2024
2024-12-06HemoSonics LLC$203Research paymentCash or cash equivalentQUNATRA QPLUS SYSTEM Device, HEMATOLOGYEvaluation of the Clinical Performance of the Quantra System with the QSTAT Cartridge in Obstetric Patients2024
2024-12-05ABBVIE INC.$25,285Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant2024
2024-12-05PFIZER INC.$8,801Research paymentCash or cash equivalentA PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 069399262024
2024-12-05ABBVIE INC.$8,094Research paymentCash or cash equivalentA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi2024
2024-12-05Applied Medical Resources Corporation$6,375Research paymentIn-kind items and servicesAlexis Orthopaedic Protector Device, ALEXIS PROTECTION & RETRACTION2024
2024-12-05CSL Behring$885Research paymentCash or cash equivalentHEMGENIX Biological, HematologyPhase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral 2024
2024-12-05PFIZER INC.$880Research paymentCash or cash equivalentADCETRIS Biological, OncologyMULTIPLE PART CLINICAL TRIAL OF BRENTUXIMAB VEDOTIN IN CLASSICAL HODGKIN LYMPHOMA SUBJECTS2024

The latest 200 records of 2,581.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Salt Lake CountySalt Lake City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.

MeasurePlace (city or town)
Salt Lake City, UT
County
Salt Lake County, UT
State
Utah
Population B01003208,0071,196,5233,392,331
Population, 2020 census P1199,7231,185,2383,271,616
Median age B0100232.934.032.0
Under 18 B0100116.4%25.3%27.8%
65 and over B0100112.5%11.9%11.9%
Households B1100192,652426,2451,124,822
Foreign born B0500214.9%13.5%8.9%
Median household income B19013$75,090$97,494$95,166
Median family income B19113$109,291$116,682$109,675
Per capita income B19301$51,173$45,106$40,873
Poverty rate B1700113.6%8.1%8.5%
Unemployment rate B230254.2%3.8%3.6%
Civilian labor force B23025129,830670,9001,778,106
Mean commute (minutes) B0801319.522.322.1
Bachelor's degree or higher B1500351.5%39.4%37.7%
Housing units B25001101,188449,6621,223,468
Owner-occupied B2500345.8%66.1%70.2%
Renters B2500354.2%33.9%29.8%
Median home value B25077$539,500$525,700$489,400
Median gross rent B25064$1,414$1,592$1,496
White, not Hispanic B0300264.4%66.6%74.7%
Black B030022.3%1.7%1.1%
Hispanic or Latino B0300220.8%20.6%15.9%
Asian B030024.9%4.2%2.4%
American Indian and Alaska Native B030020.5%0.5%0.6%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.